BCMA CHO Recombinant Cell Line (High or Low Expression)
BCMA CHO Cell Line is a clonal stable CHO cell line constitutively expressing full length human BCMA protein, also known as TNFRSF17, (Genbank #NM_001192). Surface expression of BCMA was confirmed by flow cytometry. Each stable clonal cell line was selected for different levels of BCMA expression, (High or Low), to mimic different stages of cancer target cells with various BCMA expression levels.
This product has been cited 3 times.
Purchase of this cell line is for research purposes only; commercial use requires a separate license. View the full terms and conditions.
Media Required for Cell Culture
Name | Ordering Information |
Thaw Medium 3 | BPS Bioscience #60186 |
Growth Medium 3D | BPS Bioscience #79539 |
Materials Required for Cellular Assay
Name | Ordering Information |
NFAT Reporter (Luc) – Jurkat Recombinant Cell Line | BPS Bioscience #60621 |
Thaw Medium 2 | BPS Bioscience #60184 |
Anti-BCMA/Anti-CD3 Bispecific Antibody | BPS Bioscience #100689 |
96-well tissue culture-treated white clear-bottom assay plate | |
PE-conjugated anti-human BCMA (CD269) antibody | Biolegend #357504 |
ONE-Step™ Luciferase Assay System | BPS Bioscience #60690 |
Luminometer |
The cell line has been screened to confirm the absence of Mycoplasma species.
B-cell maturation antigen (BCMA), also known as CD269 or tumor necrosis factor receptor superfamily member 17 (TNFRSF17), is a cell surface receptor of the TNF receptor superfamily that recognizes B-cell activating factor (BAFF). BCMA is preferentially expressed in mature B lymphocytes and also on Multiple Myeloma (MM) cells. BCMA is a highly attractive target antigen for immunotherapy because of its restricted expression in non-malignant tissue but almost universal expression on MM cells. CAR (chimeric antigen receptor)-T BCMA cells are an autologous T cell product engineered by lentiviral transduction to express a fully human BCMA-specific CAR. CAR-T cells targeting BCMA have pre-clinical anti-MM activity, and in 2017, the FDA granted BCMA CAR T-Cell immunotherapy breakthrough designation in Multiple Myeloma.
Ghosh A., et al. 2017 Leuk Lymphoma. 6:1-12
Sanchez E., et al., 2018 Expert Rev Mol Diagn. 7:1-11.
Sohail A., et al., 2018 Immunotherapy. 10(4):265-282.
Sidaway P., et al. 2016 Nat Rev Clin Oncol. 13(9):530.